查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611097

苯酮尿症治療市場規模、佔有率、趨勢分析報告：按藥物、劑型、地區和細分市場預測，2025-2030年

Phenylketonuria Treatment Market Size, Share & Trends Analysis Report By Drug (Kuvan, Palynziq), By Mode of Administration (Oral Administration, Parenteral Administration), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

苯酮尿症 (PKU) 治療市場成長和趨勢

Grand View Research, Inc.最新報告顯示，到2030年，全球苯酮尿症治療市場規模預計將達到8.51億美元，2025年至2030年複合年成長率為9.4%。全球 PKU 盛行率不斷上升，有利的政府法規預計將在預測期內推動市場成長。

例如，根據 FDA 的數據，2018 年美國大約每 10,000 至 15,000 人中就有 1 人患有苯酮尿症。此外，根據 Orphanet 報告，估計歐洲每 10,000 名新生兒中就有 1 人受到 PKU 的影響。此病在義大利、愛爾蘭、土耳其等歐洲國家發病率較高。據估計，土耳其每 4,000 人中約有 1 人被診斷出患有 PKU。

私人和公共組織開展的各種意識計劃預計也將推動市場成長。進行此類計畫的組織包括 SickKids、威斯康辛州兒童醫院、CHOC 兒童醫院和波士頓兒童醫院。這些計劃旨在讓 PKU 患者保持最佳的心理、發展和身體健康。

此外，疾病治療的持續研究和開發預計將推動市場成長。例如，Synlogic, Inc.的SYNB1618正在進行1/2a期臨床試驗，也獲得了FDA的簡審類。此外，Rubius Therapeutics, Inc.、Retropin, Inc. 和 Homology Medicines, Inc. 等其他公司正在進行研究開發新療法，包括口服療法、酵素療法和基因療法。

預計 PKU 高成本治療的報銷措施也將促進市場成長。 Kuban 目前在許多歐洲國家核准使用和報銷，包括德國、比利時、法國、義大利和奧地利。此外，預計各組織增加的研究和開發資助計劃將推動市場的發展。例如，全國 PKU 聯盟資助研究計劃，幫助推進 PKU 管理和治療的進步。

苯酮尿症治療市場報告亮點

  • Palynziq 將在 2024 年佔據最大佔有率，達到 67.9%，預計在預測期內將以顯著的複合年成長率成長。
  • 由於成熟的醫療基礎設施、高昂的醫療成本和有利的政府法規，2024 年苯酮尿症治療市場將由北美主導。
  • 由於 PKU開發新藥的研發活動活性化，預計歐洲在預測期內將呈現最快的複合年成長率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章苯酮尿症治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章苯酮尿症治療市場：醫藥業務分析

  • 2024年及2030年藥品市場佔有率
  • 醫藥細分儀表板
  • 2018-2030 年按藥物分類的市場規模、預測與趨勢分析
  • 庫萬
  • 帕林吉庫
  • 其他

第5章苯酮尿症治療市場：劑量方法業務分析

  • 2024年及2030年劑量方法市場佔有率
  • 計量方法細分儀表板
  • 2018-2030 年市場規模、預測與趨勢分析（按管理方式）
  • 口服給藥
  • 腸外給藥

第6章 苯酮尿症治療市場：按藥物和給藥方法分類的區域估計和趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • BioMarin
    • Synlogic
    • Travere Therapeutics, Inc.
    • DAIICHI SANKYO COMPANY, LIMITED.
    • Codexis, Inc.
    • SOM BIOTECH
    • Homology Medicines, Inc.（Q32 Bio Inc.）
Product Code: GVR-3-68038-310-2

Phenylketonuria Treatment Market Growth & Trends:

The global phenylketonuria treatment market size is expected to reach USD 851.0 million by 2030, registering a CAGR of 9.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of PKU across the world and favorable government regulations are the factors expected to spur the market growth over the forecast period.

For instance, according to the FDA, in 2018, phenylketonuria affected about 1 in 10,000 to 15,000 people in U.S. Furthermore, according to the Orphanet, it was estimated that 1 in 10,000 newborns in Europe is suffering from PKU. The target disease is highly prevalent in European countries, such as Italy, Ireland, and Turkey. It was estimated that around 1 in 4000 individuals in Turkey were diagnosed with PKU.

Various awareness programs conducted by private and public organizations are also projected to fuel market growth. Some of the organizations conducting such programs are SickKids, Children's Hospital of Wisconsin, CHOC Children's, and Boston Children's Hospital. These programs aim to promote optimal emotional, developmental, and physical health PKU patients.

Furthermore, continuous R&D for the disease treatment is estimated to enhance the market growth. For instance, Synlogic, Inc.'s SYNB1618 drug is undergoing Phase 1/2a clinical trials and also received fast-track designation from FDA. In addition, other companies, such as Rubius Therapeutics, Inc., Retrophin, Inc., and Homology Medicines, Inc. are also conducting research to develop novel therapies, such as oral, enzyme therapy, gene therapy.

Availability of reimbursement policies for high-cost treatments of PKU is also projected to boost the market growth. Kuvan is currently approved for use and reimbursed in many European countries, such as Germany, Belgium, France, Italy, and Austria. Furthermore, increasing number of funding programs for R&D by various organizations is anticipated to drive the market. For instance, the National PKU Alliance provides funding to research projects that helps in promoting advances in the management and treatment of PKU.

Phenylketonuria Treatment Market Report Highlights:

  • Palynziq accounted for the largest share of 67.9% in 2024 and is also expected to grow at a significant CAGR over the forecast period.
  • North America dominated the phenylketonuria treatment market in 2024 owing to the presence of well-established healthcare infrastructure, high healthcare expenditure, and favorable government regulations
  • Europe region is expected to exhibit the fastest CAGR over the forecast period owing to rising R&D activities for the development of new PKU drugs

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Mode of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Phenylketonuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Phenylketonuria Treatment Market: Drug Business Analysis

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Drug Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 4.4. Kuvan
    • 4.4.1. Kuvan market, 2018 - 2030 (USD Million)
  • 4.5. Palynziq
    • 4.5.1. Palynziq market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Phenylketonuria Treatment Market: Mode of Administration Business Analysis

  • 5.1. Mode of Administration Market Share, 2024 & 2030
  • 5.2. Mode of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mode of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Administration
    • 5.4.1. Oral administration market, 2018 - 2030 (USD Million)
  • 5.5. Parenteral Administration
    • 5.5.1. Parenteral administration market, 2018 - 2030 (USD Million)

Chapter 6. Phenylketonuria Treatment Market: Regional Estimates & Trend Analysis by Drug and Mode of Administration

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. U.S. phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. Canada phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. Mexico phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. UK phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. Germany phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. France phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. Italy phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Spain phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Denmark phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework
      • 6.5.8.3. Competitive insights
      • 6.5.8.4. Sweden phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key country dynamics
      • 6.5.9.2. Regulatory framework
      • 6.5.9.3. Competitive insights
      • 6.5.9.4. Norway phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Japan phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. China phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive insights
      • 6.6.4.4. India phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive insights
      • 6.6.5.4. Australia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive insights
      • 6.6.6.4. South Korea phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive insights
      • 6.6.7.4. Thailand phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. Brazil phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Argentina phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive insights
      • 6.8.2.4. South Africa phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive insights
      • 6.8.3.4. Saudi Arabia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive insights
      • 6.8.4.4. UAE phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key country dynamics
      • 6.8.5.2. Regulatory framework
      • 6.8.5.3. Competitive insights
      • 6.8.5.4. Kuwait phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. BioMarin
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Synlogic
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Travere Therapeutics, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. DAIICHI SANKYO COMPANY, LIMITED.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. Codexis, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. SOM BIOTECH
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. Homology Medicines, Inc. (Q32 Bio Inc.)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global phenylketonuria treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 5 Global phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 6 North America Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 8 North America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 9 U.S. phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 10 U.S. phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 12 Canada phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Europe phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 18 UK phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 19 UK phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 20 Germany phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 22 France phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 23 France phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 24 Italy phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 25 Italy phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 26 Spain phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Spain phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 28 Denmark phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 29 Denmark phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 30 Sweden phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 31 Sweden phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 32 Norway phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Norway phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 37 Japan phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 38 Japan phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 39 China phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 40 China phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 41 India phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 42 India phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 43 Australia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 44 Australia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 46 South Korea phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 47 Thailand phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 48 Thailand phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Latin America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 53 Brazil phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 54 Argentina phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 55 Argentina phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 59 South Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 60 South Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 63 UAE phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 64 UAE phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 65 Kuwait phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 66 Kuwait phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Phenylketonuria treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug outlook (USD Million)
  • Fig. 10 Mode of administration outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Phenylketonuria treatment market dynamics
  • Fig. 13 Phenylketonuria treatment market: Porter's five forces analysis
  • Fig. 14 Phenylketonuria treatment market: PESTLE analysis
  • Fig. 15 Phenylketonuria treatment market: Drug segment dashboard
  • Fig. 16 Phenylketonuria treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 17 Kuvan market, 2018 - 2030 (USD Million)
  • Fig. 18 Palynziq market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Phenylketonuria treatment market: Mode of administration segment dashboard
  • Fig. 21 Phenylketonuria treatment market: Mode of administration market share analysis, 2024 & 2030
  • Fig. 22 Oral administration market, 2018 - 2030 (USD Million)
  • Fig. 23 Parenteral administration market, 2018 - 2030 (USD Million)
  • Fig. 24 Phenylketonuria treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key country dynamics
  • Fig. 77 Kuwait phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework